2. シグナル伝達
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC 関連カスタムサービス

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
製品番号 製品名 製品効果 純度 構造式
  • HY-177682
    N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
    N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
    N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
  • HY-141593
    Modified MMAF-C5-COOH
    Modified MMAF-C5-COOH is a agent-linker conjugate for ADC.
    Modified MMAF-C5-COOH
  • HY-153067
    Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan
    Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan (Compound 11) is a bioactive compound-linker conjugate for ADC. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can conjugate with antibodies to form ADC (C-11) with anti-tumor activity. Exatecan is a DNA Topoisomerase I inhibitor. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can be used in the research of squamous cell carcinoma, pancreatic adenocarcinoma and colorectal cancer.
    Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan
  • HY-160683
    MC-Gly-Gly-Phe-Gly-NH-CH2-O-amide-Eribulin
    MC-Gly-Gly-Phe-Gly-NH-CH2-O-amide-Eribulin (Compound 7) can be used as a linker-drug intermediate for the synthesis of antibody-drug conjugates (ADCs).
    MC-Gly-Gly-Phe-Gly-NH-CH2-O-amide-Eribulin
  • HY-125858B
    (S,R,S)-MI-1061
    (S,R,S)-MI-1061 is the isomer of MI-1061(HY-125858). (S,R,S)-MI-1061 can used to synthesize Antibody-Drug Conjugates (ADCs). MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity.
    (S,R,S)-MI-1061
  • HY-P11779A
    Ac-RKAA-PABC-MMAE TFA
    Ac-RKAA-PABC-MMAE TFA is a Drug-Linker Conjugates for ADC. Ac-RKAA-PABC-MMAE TFA consists of the ADC Cytotoxin MMAE (HY-15162) and a linker. Ac-RKAA-PABC-MMAE TFA can be used for synthesis of ADCs.
    Ac-RKAA-PABC-MMAE TFA
  • HY-173079
    TLR7 agonist 30
    TLR7 agonist 30 (compound 2) is an agent-linker conjugate for ADC. TLR7 agonist 30 contains a TLR7 agonist (compound 1) and a cleavable linker, and has potent anti-tumor activity.
    TLR7 agonist 30
  • HY-156896
    Val-Cit-amide-Cbz-N(Me)-Maytansine
    Val-Cit-amide-Cbz-N(Me)-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs).
    Val-Cit-amide-Cbz-N(Me)-Maytansine
  • HY-181429
    Fmoc-Gly-Gly-Phe-Gly-Paclitaxel
    Fmoc-Gly-Gly-Phe-Gly-Paclitaxel (Compound 16a-3) is a drug-linker conjugates for ADC. Fmoc-Gly-Gly-Phe-Gly-Paclitaxel contains the ADC linker Fmoc-Gly-Gly-Phe-OH (HY-131833) and a potent tubulin polymerization inhibitor Paclitaxel (HY-B0015). Fmoc-Gly-Gly-Phe-Gly-Paclitaxel can be used for the research of cancer.
    Fmoc-Gly-Gly-Phe-Gly-Paclitaxel
  • HY-182806
    Demethylation-desulfuration-α-Amanitin-OH-PAB-Ala-Val-CO-C2-mal
    Demethylation-desulfuration-α-Amanitin-OH-PAB-Ala-Val-CO-C2-mal is a conjugate of an ADC drug toxin molecule and a linker, containing a degradable PEG linker and the toxin molecule M-4, which is a cyclic peptide derived from α-Amanitin (HY-19610).
    Demethylation-desulfuration-α-Amanitin-OH-PAB-Ala-Val-CO-C2-mal
  • HY-160702
    DMBA-SIL-Mal-MMAE
    DMBA-SIL-Mal-MMAE is a cytotoxin-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked DMBA-SIL-Mal.
    DMBA-SIL-Mal-MMAE
  • HY-167966
    Mal-TLR7 agonist 32
    Mal-TLR7 agonist 32 is a drug-linker conjugate that consists of a TLR7 agonist (HY-167774) and a linker. Mal-TLR7 agonist 32 can be used in synthesis of ADC.
    Mal-TLR7 agonist 32
  • HY-128941
    CCK2R Ligand-Linker Conjugates 1
    CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker.
    CCK2R Ligand-Linker Conjugates 1
  • HY-177688
    N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan)
    N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
    N-(NHS-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan)
  • HY-176927
    ADC-VI
    ADC-VI (Compound 6) is a conjugate of a toxic molecule and a linker, in which the cytotoxin carried by CPD6 is Deruxtecan (HY-13631E). Tricyclene is used to form an antibody-drug conjugate (ADC) by a chemical conjugation reaction through linking with an anti-FGFR2b antibody.
    ADC-VI
  • HY-126493
    DM4-SPDP
    DM4-SPDP is a Drug-Linker Conjugates for ADC. DM4-SPDP consists of the ADC cytotoxin DM4 (HY-12454) and a linker SPDP (HY-100216). DM4-SPDP can be used for synthesis of ADCs.
    DM4-SPDP
  • HY-176202
    TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC
    TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC (compound LIV1-IMC (12) linker-payload) is a linker-payload conjugate, used in the synthesis of antibody-drug conjugates (ADCs).TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC contains TLR7/8 agonist (HY-170770) (ADC payload) and a linker (HY-176478).
    TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC
  • HY-177680
    N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
    N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
    N-(Mal-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
  • HY-131085
    Desmethyl Vc-seco-DUBA
    Desmethyl Vc-seco-DUBA consists a cleavable ADC linker (Desmethyl Vc-seco) and a DNA alkylating agent (DUBA). Desmethyl Vc-seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs).
    Desmethyl Vc-seco-DUBA
  • HY-155744
    Acetylene-PEG3-MMAF-OMe
    Acetylene-PEG3-MMAF-OMe (LCB14-0536) is a protein-active agent conjugate. Acetylene-PEG3-MMAF-OMe can be recognized by isoprenoid transferase. Acetylene-PEG3-MMAF-OMe is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Acetylene-PEG3-MMAF-OMe
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.